Rocket Pharmaceuticals (RCKT) Preferred Stock Liabilities (2014 - 2015)
Rocket Pharmaceuticals (RCKT) posted Preferred Stock Liabilities of $46.4 million for Q3 2015, up 8364.05% sequentially from $548000.0 in Q2 2015.
Powered by 
Analysis
Rocket Pharmaceuticals (RCKT) Preferred Stock Liabilities (2014 - 2015) Analysis & Trends
Rocket Pharmaceuticals has reported Preferred Stock Liabilities for 2 years, with the latest figure at $46.4 million in Q3 2015.
- Quarterly Preferred Stock Liabilities changed N/A year-over-year to $46.4 million in Q3 2015, while the trailing twelve-month figure through Sep 2015 was $46.4 million (changed N/A YoY) and the FY2014 annual result came in at $46.8 million, changed N/A from the prior year.
- Preferred Stock Liabilities grew to $46.4 million in Q3 2015 per RCKT's latest filing, from $548000.0 in the prior quarter.
- Over five years, Preferred Stock Liabilities peaked at $46.8 million in Q4 2014 and troughed at $548000.0 in Q2 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Rocket Pharmaceuticals | 437.27 Mn | 437.27 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2015 | 46.38 Mn |
| Jun 30, 2015 | 46.38 Mn |
| Mar 31, 2015 | 46.38 Mn |
| Dec 31, 2014 | 46.80 Mn |